CD274 and neoplasm: Programmed death 1 (PD-1) and its ligand PD-L1 are highly expressed in the tumor microenvironment of mRCC based on a study using samples from Japanese patients [5] and from the Cancer Genome Atlas [6], indicating that PD-1/PD-L1 inhibitors may be effective in this cancer type.